Publicaciones en las que colabora con Vicente Molina Rodríguez (42)

2023

  1. Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 273, Núm. 6, pp. 1379-1386

2022

  1. Relation between EEG resting-state power and modulation of P300 task-related activity in theta band in schizophrenia

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 116

2021

  1. Neurobiological underpinnings of cognitive subtypes in psychoses: A cross-diagnostic cluster analysis

    Schizophrenia Research, Vol. 229, pp. 102-111

2020

  1. Deficits of entropy modulation of the EEG: A biomarker for altered function in schizophrenia and bipolar disorder?

    Journal of Psychiatry and Neuroscience, Vol. 45, Núm. 5, pp. 322-333

2019

  1. Pattern of use of clozapine in Spain. Variability and under-prescription

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 3, pp. 151-162

2016

  1. Elevated midline-parietal gamma band noise power in schizophrenia but not in bipolar patients

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, Núm. 8, pp. 743-753

2014

  1. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia

    Schizophrenia Research, Vol. 158, Núm. 1-3, pp. 223-229

2013

  1. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: Results after one year

    Schizophrenia Research, Vol. 149, Núm. 1-3, pp. 156-161

2012

  1. Clozapine as treatment of first choice in first psychotic episodes. What do we know?

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 5, pp. 281-289

2009

  1. Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 173, Núm. 2, pp. 88-93

2008

  1. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

    International Clinical Psychopharmacology, Vol. 23, Núm. 3, pp. 138-149

  2. Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 1, pp. 257-266

  3. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13)

    Genes, Brain and Behavior, Vol. 7, Núm. 7, pp. 796-801

2007

  1. Changes in cortical volume with olanzapine in chronic schizophrenia

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 135-139

  2. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder

    European Psychiatry, Vol. 22, Núm. 8, pp. 505-512

  3. Effect of interleukin-1β gene functional polymorphism on dorsolateral prefrontal cortex activity in schizophrenic patients

    American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 144, Núm. 8, pp. 1090-1093

  4. Marked hypofrontality in clozapine-responsive patients

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 157-162

  5. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia

    Neuropsychobiology, Vol. 54, Núm. 3, pp. 171-178

2006

  1. Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, Núm. 2, pp. 106-111

2005

  1. Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia

    European Psychiatry, Vol. 20, Núm. 4, pp. 332-338